MBX Biosciences (NASDAQ: MBX) director awarded RSUs and 74,249 stock options
Rhea-AI Filing Summary
MBX Biosciences director Steven L. Hoerter reported new equity awards and existing holdings. He received a grant of 11,938 shares of Common Stock as restricted stock units, which will vest in full on November 6, 2026, subject to his continued service.
He was also granted stock options covering 74,249 shares of Common Stock at an exercise price of $29.78 per share, expiring on May 1, 2036. This option grant vests 50% on the grant date and the remaining 50% in equal monthly installments over six months, conditioned on continued service. Separately, 20,000 Common Stock shares are held indirectly through the Steven L Hoerter Revocable Trust, where he serves as trustee and disclaims beneficial ownership except for any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 11,938 shares
Net Buy
3 txns
Insider
Hoerter Steven L.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) | 74,249 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 11,938 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock option (right to buy) — 74,249 shares (Direct);
Common Stock — 11,938 shares (Direct);
Common Stock — 20,000 shares (Indirect, Trust)
Footnotes (3)
- F1. Represents the grant of restricted stock units (RSUs). The RSUs will vest in full on November 6, 2026, subject to the Reporting Person's continued service on such vesting date.
- F2. Shares held by the Steven L Hoerter Revocable Trust dated November 2, 2018, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- F3. The grant will vest 50% upon grant date and the remaining 50% in equal monthly installments over a six-month period from the grant date, subject to the Reporting Person's continued services to the Company.
Key Figures
RSU grant: 11,938 shares
Stock option grant size: 74,249 shares
Option exercise price: $29.78 per share
+3 more
6 metrics
RSU grant
11,938 shares
Restricted stock units vesting on November 6, 2026
Stock option grant size
74,249 shares
Options on Common Stock granted to director
Option exercise price
$29.78 per share
Stock option (right to buy) exercise price
Option expiration
May 1, 2036
Stock option expiration date
Trust-held shares
20,000 shares
Common Stock held by Steven L Hoerter Revocable Trust
Direct shares after RSU grant
11,938 shares
Total direct Common Stock holdings following RSU award
Key Terms
restricted stock units (RSUs), Revocable Trust, vest, stock option (right to buy), +1 more
5 terms
restricted stock units (RSUs) financial
"Represents the grant of restricted stock units (RSUs). The RSUs will vest in full on November 6, 2026"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
Revocable Trust financial
"Shares held by the Steven L Hoerter Revocable Trust dated November 2, 2018"
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
vest financial
"The RSUs will vest in full on November 6, 2026, subject to the Reporting Person's continued service"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
stock option (right to buy) financial
"Stock option (right to buy) with underlying security title Common Stock"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider equity awards did MBX director Steven L. Hoerter receive?
Steven L. Hoerter received 11,938 restricted stock units and options for 74,249 MBX Biosciences shares. The RSUs vest in full on November 6, 2026, while the options vest 50% at grant and 50% monthly over six months, subject to continued service.
When do Steven L. Hoerter’s MBX restricted stock units vest?
Hoerter’s 11,938 MBX Biosciences restricted stock units vest in full on November 6, 2026. Vesting is contingent on his continued service with the company through that date, aligning the award with long-term retention and performance incentives.
What are the key terms of Steven L. Hoerter’s MBX stock option grant?
Hoerter’s MBX stock option grant covers 74,249 shares at an exercise price of $29.78 per share, expiring May 1, 2036. The grant vests 50% on the grant date and the remaining 50% in equal monthly installments over six months, subject to continued services.
Does this MBX Form 4 show any open-market buying or selling by Steven L. Hoerter?
The Form 4 reports equity awards and existing holdings, not open-market trades, for Steven L. Hoerter. It includes grants of restricted stock units and stock options, plus indirect trust-held shares, reflecting compensation and ownership structure rather than market purchases or sales.